These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 29700899)

  • 41. Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study.
    Otaify GA; Aglan MS; Ibrahim MM; Elnashar M; El Banna RA; Temtamy SA
    Osteoporos Int; 2016 Jan; 27(1):81-92. PubMed ID: 26138583
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intravenous pamidronate therapy in Taiwanese patients with osteogenesis imperfecta.
    Lin HY; Lin SP; Chuang CK; Chen MR; Chang CY
    Pediatr Neonatol; 2008 Oct; 49(5):161-5. PubMed ID: 19133566
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pamidronate treatment of severe osteogenesis imperfecta in a newborn infant.
    Chien YH; Chu SY; Hsu CC; Hwu WL
    J Inherit Metab Dis; 2002 Nov; 25(7):593-5. PubMed ID: 12638943
    [No Abstract]   [Full Text] [Related]  

  • 44. The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta type V.
    Zeitlin L; Rauch F; Travers R; Munns C; Glorieux FH
    Bone; 2006 Jan; 38(1):13-20. PubMed ID: 16162424
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pamidronate treatment of children with moderate-to-severe osteogenesis imperfecta: a note of caution.
    Alharbi M; Pinto G; Finidori G; Souberbielle JC; Guillou F; Gaubicher S; Le Merrer M; Polak M
    Horm Res; 2009 Jan; 71(1):38-44. PubMed ID: 19039235
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Respiratory failure during infusion of pamidronate in a 3 year-old male with osteogenesis imperfecta: a case report.
    Olson JA
    J Pediatr Rehabil Med; 2014; 7(2):155-8. PubMed ID: 25096867
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta.
    DiMeglio LA; Ford L; McClintock C; Peacock M
    Bone; 2004 Nov; 35(5):1038-45. PubMed ID: 15542028
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Osteogenesis imperfecta.
    Glorieux FH
    Best Pract Res Clin Rheumatol; 2008 Mar; 22(1):85-100. PubMed ID: 18328983
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Osteogenesis imperfecta: a new, early therapeutic approach with biphosphonates. A case report].
    Guillot M; Eckart P; Desrosieres H; Amiour M; al-Jazayri Z
    Arch Pediatr; 2001 Feb; 8(2):172-5. PubMed ID: 11232458
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Therapy with pamidronate in children with osteogenesis imperfecta.
    Marginean O; Tamasanu RC; Mang N; Mozos I; Brad GF
    Drug Des Devel Ther; 2017; 11():2507-2515. PubMed ID: 28894358
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Benefit of infusions with ibandronate treatment in children with osteogenesis imperfecta.
    Li M; Xia WB; Xing XP; Yu W; Hu YY; Jiang Y; Wang O; Liu HJ; Han LW; Meng XW; Xu L
    Chin Med J (Engl); 2011 Oct; 124(19):3049-53. PubMed ID: 22040553
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Successful results of pamidronate treatment in children with osteogenesis imperfecta with emphasis on the interpretation of bone mineral density for local standards.
    Poyrazoglu S; Gunoz H; Darendeliler F; Bas F; Tutunculer F; Eryilmaz SK; Bundak R; Saka N
    J Pediatr Orthop; 2008 Jun; 28(4):483-7. PubMed ID: 18520289
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intravenous pamidronate therapy in osteogenesis imperfecta: response to treatment and factors influencing outcome: a novel molecular mechanism.
    Namazi H
    J Pediatr Orthop; 2009 Sep; 29(6):650-1. PubMed ID: 19700999
    [No Abstract]   [Full Text] [Related]  

  • 54. Effect of cyclical intravenous pamidronate therapy in children with osteogenesis imperfecta. Open-label study in seven patients.
    Giraud F; Meunier PJ
    Joint Bone Spine; 2002 Oct; 69(5):486-90. PubMed ID: 12477233
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of low dose schedule pamidronate infusion in children with osteogenesis imperfecta.
    González E; Pavía C; Ros J; Villaronga M; Valls C; Escolá J
    J Pediatr Endocrinol Metab; 2001 May; 14(5):529-33. PubMed ID: 11393574
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
    Glorieux FH; Bishop NJ; Plotkin H; Chabot G; Lanoue G; Travers R
    N Engl J Med; 1998 Oct; 339(14):947-52. PubMed ID: 9753709
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Growth of infants with osteogenesis imperfecta treated with bisphosphonate.
    Hasegawa K; Inoue M; Seino Y; Morishima T; Tanaka H
    Pediatr Int; 2009 Feb; 51(1):54-8. PubMed ID: 19371278
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Treatment of osteogenesis imperfecta with bisphosphonates].
    Tau C
    Medicina (B Aires); 2007; 67(4):389-95. PubMed ID: 17891938
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biochemical bone markers in the assessment and pamidronate treatment of children and adolescents with osteogenesis imperfecta.
    Aström E; Magnusson P; Eksborg S; Söderhäll S
    Acta Paediatr; 2010 Dec; 99(12):1834-40. PubMed ID: 20726960
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Hearing is not affected by diphosphonates in osteogenesis imperfecta. Retrospective study of 42 medical records].
    Brodd I; Hederstierna C; Sääf M; Hultcrantz M
    Lakartidningen; 2011 Sep 28-Oct 4; 108(39):1906-9. PubMed ID: 22111228
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.